PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

Recruiting now

Conditions studied: Persistent Pulmonary Hypertension of the Newborn

In brief

The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).

Key facts

Study ID

NCT00710177

Run by

Medical College of Wisconsin

People needed

200

Starts

2006-01-01

Expected to finish

2028-12-01

Last updated by the study team

2026-01-26

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age.

You may not qualify if…

• Patients will be excluded if they are diagnosed with lethal congenital anomalies
• structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale
• structural gastrointestinal tract abnormality that could interfere with meconium passage
• congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia

Where it is running

• Children's Wisconsin — Milwaukee, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.